Markers of endothelial glycocalyx dysfunction in Clarkson disease.
Capillary leak
Endothelium
Glyocalcyx
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
29 08 2022
29 08 2022
Historique:
received:
18
05
2022
accepted:
12
08
2022
entrez:
29
8
2022
pubmed:
30
8
2022
medline:
1
9
2022
Statut:
epublish
Résumé
Clarkson disease (monoclonal gammopathy-associated idiopathic systemic capillary leak syndrome, ISCLS) is a rare idiopathic condition marked by transient, relapsing-remitting episodes of systemic microvascular hyper-permeability, which liberates plasma fluid and macromolecules into the peripheral tissues. This pathology manifests clinically as the abrupt onset of hypotensive shock, hemoconcentration, and hypoalbuminemia. We analysed endothelial glycocalyx (eGCX)-related markers in plasma from patients with ISCLS during acute disease flares and convalescence by ELISA and comprehensive proteomic profiling. We evaluated eGCX-related components and gene expression in cultured endothelial cells using RNA-sequencing, real-time PCR, and fluorescence staining. Serum levels of eGCX-related core components including hyaluronic acid (HA) and the core proteoglycan soluble syndecan-1 (sCD138) were elevated at baseline and during acute ISCLS flares. Serial measurements demonstrated that sCD138 levels peaked during the recovery (post-leak) phase of the illness. Proteomic analysis of matched acute and convalescent ISCLS plasma revealed increased abundance of eGCX-related proteins, including glypicans, thrombospondin-1 (TSP-1), and eGCX-degrading enzymes in acute compared to remission plasma. Abundance of endothelial cell damage markers did not differ in acute and baseline plasma. Expression of several eGCX-related genes and surface carbohydrate content in endothelial cells from patients with ISCLS did not differ significantly from that observed in healthy control cells. eGCX dysfunction, but not endothelial injury, may contribute to clinical symptoms of acute ISCLS. Serum levels of of eGCX components including sCD138 may be measured during acute episodes of ISCLS to monitor clinical status and therapeutic responses.
Sections du résumé
BACKGROUND
Clarkson disease (monoclonal gammopathy-associated idiopathic systemic capillary leak syndrome, ISCLS) is a rare idiopathic condition marked by transient, relapsing-remitting episodes of systemic microvascular hyper-permeability, which liberates plasma fluid and macromolecules into the peripheral tissues. This pathology manifests clinically as the abrupt onset of hypotensive shock, hemoconcentration, and hypoalbuminemia.
METHODS
We analysed endothelial glycocalyx (eGCX)-related markers in plasma from patients with ISCLS during acute disease flares and convalescence by ELISA and comprehensive proteomic profiling. We evaluated eGCX-related components and gene expression in cultured endothelial cells using RNA-sequencing, real-time PCR, and fluorescence staining.
RESULTS
Serum levels of eGCX-related core components including hyaluronic acid (HA) and the core proteoglycan soluble syndecan-1 (sCD138) were elevated at baseline and during acute ISCLS flares. Serial measurements demonstrated that sCD138 levels peaked during the recovery (post-leak) phase of the illness. Proteomic analysis of matched acute and convalescent ISCLS plasma revealed increased abundance of eGCX-related proteins, including glypicans, thrombospondin-1 (TSP-1), and eGCX-degrading enzymes in acute compared to remission plasma. Abundance of endothelial cell damage markers did not differ in acute and baseline plasma. Expression of several eGCX-related genes and surface carbohydrate content in endothelial cells from patients with ISCLS did not differ significantly from that observed in healthy control cells.
CONCLUSIONS
eGCX dysfunction, but not endothelial injury, may contribute to clinical symptoms of acute ISCLS. Serum levels of of eGCX components including sCD138 may be measured during acute episodes of ISCLS to monitor clinical status and therapeutic responses.
Identifiants
pubmed: 36038904
doi: 10.1186/s12967-022-03587-1
pii: 10.1186/s12967-022-03587-1
pmc: PMC9421105
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
380Subventions
Organisme : Division of Intramural Research, National Institute of Allergy and Infectious Diseases
ID : Z01-AI-001083
Informations de copyright
© 2022. The Author(s).
Références
Cardiovasc Res. 2021 May 25;117(6):1592-1605
pubmed: 32647868
Microvasc Res. 2017 Jul;112:72-78
pubmed: 28347755
Front Cell Dev Biol. 2021 Sep 13;9:730621
pubmed: 34589494
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Sci Rep. 2021 Dec 21;11(1):24379
pubmed: 34934165
Database (Oxford). 2016 Jul 03;2016:
pubmed: 27374120
Am J Med. 2017 Oct;130(10):1219.e19-1219.e27
pubmed: 28602874
Crit Care. 2022 Jan 30;26(1):33
pubmed: 35094711
Blood. 2012 May 3;119(18):4321-32
pubmed: 22411873
QJM. 2003 Apr;96(4):253-67
pubmed: 12651970
J Clin Med. 2019 Aug 27;8(9):
pubmed: 31462009
Intensive Care Med Exp. 2019 Jan 7;7(1):2
pubmed: 30618011
Crit Care Clin. 2020 Apr;36(2):217-232
pubmed: 32172810
Eur Rev Med Pharmacol Sci. 2019 May;23(10):4293-4302
pubmed: 31173301
BMJ Case Rep. 2021 May 4;14(5):
pubmed: 33947680
J Clin Cell Immunol. 2014;5:1000213
pubmed: 25405070
Nucleic Acids Res. 2013 Jul;41(Web Server issue):W77-83
pubmed: 23703215
Gastroenterol Res Pract. 2015;2015:850351
pubmed: 26294905
J Thromb Haemost. 2019 Feb;17(2):283-294
pubmed: 30582882
J Allergy Clin Immunol. 2017 Sep;140(3):663-670
pubmed: 28012935
Am J Respir Crit Care Med. 2014 May 1;189(9):1145-7
pubmed: 24787070
J Cell Mol Med. 2019 Aug;23(8):5119-5127
pubmed: 31210423
Am J Med. 2015 Jan;128(1):91-5
pubmed: 25193271
Oxid Med Cell Longev. 2017;2017:9759735
pubmed: 29333215
Am J Med. 2003 Sep;115(4):332-4
pubmed: 12967704
Front Immunol. 2021 Nov 30;12:789142
pubmed: 34917096
J Allergy Clin Immunol Pract. 2018 Mar - Apr;6(2):609-618
pubmed: 28939140
Crit Care Med. 2017 Jul;45(7):1216-1223
pubmed: 28622216
J Intern Med. 2016 Jul;280(1):97-113
pubmed: 26749537
Front Cell Dev Biol. 2021 Jul 14;9:711003
pubmed: 34336864
Am J Physiol Heart Circ Physiol. 2014 Feb;306(3):H363-72
pubmed: 24285115
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Am J Med. 1960 Aug;29:193-216
pubmed: 13693909
Matrix Biol. 2014 Jul;37:83-91
pubmed: 24476925
Pediatr Infect Dis J. 2019 Jan;38(1):89-94
pubmed: 29601451
J Thromb Haemost. 2021 Jun;19(6):1546-1557
pubmed: 33826233
Am J Case Rep. 2018 Feb 16;19:176-182
pubmed: 29449526
Ann Intensive Care. 2021 Dec 15;11(1):175
pubmed: 34910264
Diabetologia. 2010 Dec;53(12):2646-55
pubmed: 20865240
PLoS One. 2015 Jul 15;10(7):e0133266
pubmed: 26176954